Investigations of Sapindus trifoliatus in dopaminergic and serotonergic systems: Putative antimigraine mechanisms

Indian Journal of Pharmacology

Volumn 37, Issue 2, 2005, Pages 120-125

  Arulmozhi, D K ^a,b   Veeranjaneyulu, A ^a   Bodhankar, S L ^b   Arora, S K ^a  

^a LUPIN LIMITED   (India)

^b BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Dopamine; Headache; Serotonin

Indexed keywords

5 HYDROXYTRYPTOPHAN; APOMORPHINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; PLANT EXTRACT; SAPINDUS TRIFOLIATUS EXTRACT; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CLIMBING; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; DRUG SCREENING; HYPERACTIVITY; LOCOMOTION; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; SAPINDUS TRIFOLIATUS; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM;

EID: 17444369730     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.15114     Document Type: Article

References (39)

1. Stewart WF, Lipton RB. Migraine headache: Epidemiology and health care utilization. Cephalalgia 1993;13:41-6.
2. Classification and diagnostic criteria for headache disorders, cranial neurologies and facial pains. Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8:1-96.
3. Caviness VS, O' Brien P. Current Concept. Headache. N Engl J Med 1980; 302:446-50.
4. Raskin NH. Pharmacology of migraine. Annu Rev Pharmacol Toxicol 1981; 21:463-78.
5. Wilkinson M. Treatment of acute migraine attack-current status. Cephalalgia 1983; 3:61-7.
6. Goadsby PJ. How do the currently used prophylactic agents work in migraine? Cephalalgia 1997;17:85-92.
7. Peroutka SJ. Dopamine and migraine. Neurology 1997; 49:650-6.
8. Del Zompo M, Cherchi A, Palmas MA, Ponti M, Bocchetta A, Gessa GL, et al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 1998;51:781-6.
9. Russo EB. Headache treatments by native peoples of the Eucadononian amazon: A preliminary cross disciplinary assessment. J Ethnopharmacol 1992; 36:193-206.
10. Gorji A. Pharmacological treatment of headache using traditional Persian medicine. Trends Pharmacol Sci 2003;24:331-4.
11. Groenwegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in vitro. J Pharm Pharmacol 1990;42:553-7.
12. Grossman W, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Altern Med Rev 2001;6:303-10.
13. Kritikar KR, Basu BD. Indian medicinal plants. Vol. 1. New Delhi: International Book Distributors; 1999.
14. Arulmozhi DK, Veeranjaneyulu A, Bodhankar SL, Arora SK. Investigations into the antinociceptive activity of Sapindus trifoliatus in various pain models. J Pharm Pharmacol 2004;56:655-61.
15. Gupta DR, Ahmed B. Emarginatosides B and C: Two new saponins from Sapindus emarginatus fruits. Indian J Chem 1991;29:268-70.
16. Chung IW, Moore NA, Oh WK, O' Neil MF, Ahn JS, Park JB, et al. Behavioral pharmacology of polygalasaponins indicates potential antipsychotic efficacy. Pharmacol Biochem Behav 2002;71:191-5.
17. Pengsuparp T, Indra B, Nakagawasai O, Tadano T, Mimaki Y, Sashida Y, et al. Pharmacological studies of geissochizine methyl ether, isolated from Uncaria sinensis Oliv., in the central nervous system. Eur J Pharmacol 2001;425:211-8.
18. 1 agonist C-APB in mice. Psychopharmacology 1999;145:237-50.
19. Bylund DB, Toews ML. Radioligand binding methods: Practical guide and tips. Am J Physiol 1993;265:421-9.
20. Bylund DB, Murrin LC. Radioligand saturation binding experiments over large concentration ranges. Life Sci 2000;67:2897-911.
21. Zhu M, Bowery NG, Greengrass PM, Phillipson JD. Application of radioligand receptor binding assays in the search for CNS active principles from Chinese medicinal plants. J Ethnopharmacol 1996;54:153-64.
22. Arulmozhi DK, Sridhar N, Bodhankar SL, Veeranjaneyulu A, Arora SK. In vitro pharmacological investigations of Sapindus trifoliatus in various migraine targets. J Ethnopharmacol 2004 ; 95:239-45
23. Moore NA, Axton MS. The role of multiple dopamine receptors in apomorphine and N-n-propylnorapomorphine-induced climbing and hypothermia. Eur J Pharmacol 1990;178:195-201.
24. 1-dopamine receptors. Eur J Pharmacol 1998;148:221-9.
25. Yamamato T, Ueki S. The role of central serotonergic mechanism on head twitch and backward locomotion induced by hallucinogenic drugs. Pharmacol Biochem Behav 1981;14:89-95.
26. Liljequist S, Ossowska K, Grabowska-Anden M, Anden ME. Effect of NMDA receptor antagonist MK-801, on locomotor activity and metabolism of dopamine in various brain areas of mice. Eur J Pharmacol 1991;195:55-61.
27. Yan QS, Reith ME, Johe PC, Dailey JW. Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmission in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 1997;765:149-58.
28. Loscher W, Annies R, Honach D. The N-methyl-D aspartate receptor antagonist MK-801 induces increase in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett 1991;128:191-4.
29. 2A receptor antagonist MDL100907 counteracts the psychomotor stimulation ensuing manipulations with monominergic, glutamatergic or muscarinic neurotransmission in the mouse-implication for psychosis. J Neurol Transm Gen Sect 1995;100:225-37.
30. 2A receptor blockade. J Pharmacol Exp Ther 1996;277:1541-9.
31. Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, Cragg S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999;84:133-56.
32. Dahlof CG, Hargreaves RJ. Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies? Cephalalgia 1998;18:593-604.
33. Ophoff RA, Van den Maagdenberg AM, Roon KI, Ferrari MD, Frants RR. The impact of pharmacogenetics for migraine. Eur J Pharmacol 2001;9:1-10.
34. Cerbo R, Barbanti P, Buzzi MG, Fabbrini G, Brusa L, Roberti C, et al. Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin Neuropharmacol 1997;20:36-41.
35. Galeotti N, Ghelardini C, Graziol I, Uslenghi C. Indomethacin, caffeine and prochlorperazine alone and in combined revert hyperalgesia in in vivo models of migraine. Pharmacol Res 2002;46:245-50.
36. Mylecharane EJ. 5-HT2 receptor antagonist and migraine therapy. J Neurol 1991;238 Suppl 1;45-52.
37. Srikiatkhachorn A, Suwattanasophon C, Ruangpattanatawee U, Phansuwan-Pujito P. 5-HT2A receptor activation and nitric oxide synthesis: A possible mechanism determining migraine attacks. Headache 2002;42:566-74.
38. Olesen J, Iversen HK, Thomson LL. Nitric oxide supersensitivity. A possible molecular mechanism of migraine pain. Neuroreport 1993;4:1027-30.
39. Nappi G, Sandrini G, Granella F, Ruiz L, Cerutti G, Facchinetti F, et al. A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitryptyline. Headache 1990;30:439-44.